Metabolic dysfunction pathways (e.g., mTOR signaling) and prion disease pathways are also consistent with known mechanisms in ALS participants (Saxton and Sabatini, 2017; Soria et al., 2017; McAlary et al., 2020). This evidence concerns the gene MTOR and prion disease.